Market revenue in 2021 | USD 5.0 million |
Market revenue in 2028 | USD 12.0 million |
Growth rate | 13.5% (CAGR from 2021 to 2028) |
Largest segment | Adventitious virus tests |
Fastest growing segment | Adventitious Virus Tests |
Historical data | 2016 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Adventitious Virus Tests, Antibody Production Tests, Retrovirus Tests, Specific Virus Tests, Other Tests |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to virus safety testing services market will help companies and investors design strategic landscapes.
Adventitious virus tests was the largest segment with a revenue share of 36% in 2021. Horizon Databook has segmented the Singapore virus safety testing services market based on adventitious virus tests, antibody production tests, retrovirus tests, specific virus tests, other tests covering the revenue growth of each sub-segment from 2016 to 2028.
The Ministry of Health in Singapore updated its Biological Agents and Testing in 2017, which is expected to have a positive effect on the virus safety testing services market. Programs by Singapore government such as SkillsFuture—which provides training to the country’s biopharmaceutical sector workforce—are expected to further boost the biopharmaceutical industry, consequently promoting growth of virus safety testing services market.
Singapore’s pharmaceutical manufacturing is growing significantly after the launch of Biomedical Sciences (BMS) initiative. Some of the key pharma companies active in the country are Merck, GlaxoSmithKline, Sanofi-Aventis, Novartis, Schering-Plough, Pfizer, Kaneka, and Wyeth.
The entry of major players in the country is anticipated to support regional growth. For instance, in September 2018, Merck KGaA established a 3,800-square-meter GMP BioReliance biosafety testing lab in Singapore.
Horizon Databook provides a detailed overview of country-level data and insights on the Singapore virus safety testing services market , including forecasts for subscribers. This country databook contains high-level insights into Singapore virus safety testing services market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account